Published: Sat, January 06, 2018
Sport | By Cameron Gross

Integra Lifesciences (IART) Receives News Impact Score of 0.16


Therefore 53% are positive. Integra Lifesciences Holdings Corp. has $96 highest and $44.0 lowest target. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Barclays PLC reiterated an "equal weight" rating and issued a $42.00 price target (down previously from $84.00) on shares of Integra Lifesciences Holdings Corp in a research report on Friday, January 13th. Jefferies Group reissued a "buy" rating on shares of Integra Lifesciences in a research report on Sunday, September 10th. JP Morgan upgraded Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Monday, August 3 to "Overweight" rating. The company was upgraded on Wednesday, July 29 by Raymond James. The rating was maintained by RBC Capital Markets on Friday, September 1 with "Hold". The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has "Neutral" rating given on Friday, October 27 by JP Morgan. One analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. Therefore 36% are positive. The average 12-month price objective among brokers that have issued a report on the stock in the previous year is $53.50. Jefferies has "Buy" rating and $3000 target. (NYSE:MUX) has "Buy" rating given on Thursday, November 9 by H.C. Wainwright. The stock has "Buy" rating by Oppenheimer on Friday, June 23. The firm has "Neutral" rating by Goldman Sachs given on Wednesday, June 8. The firm has "Buy" rating by Oppenheimer given on Wednesday, July 26. The rating was maintained by Imperial Capital on Monday, October 10 with "Outperform". The firm has "Market Perform" rating by Wells Fargo given on Monday, October 30. The stock increased 2.42% or $2.91 during the last trading session, reaching $123.11. About 145,342 shares traded. The firm earned "Outperform" rating on Tuesday, October 13 by RBC Capital Markets. It has outperformed by 15.97% the S&P500.

Investors sentiment increased to 1.29 in Q3 2017. The stock has a market cap of $3,700.00, a price-to-earnings ratio of 77.33, a price-to-earnings-growth ratio of 1.59 and a beta of 0.65. It is positive, as 22 investors sold IART shares while 60 reduced holdings. LS Investment Advisors LLC raised its stake in Integra Lifesciences Holdings Corp by 2.9% in the third quarter. Conestoga Limited Liability Corp invested 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Stevens Capital Mngmt Ltd Partnership holds 0.02% or 12,825 shares. Deutsche Fincl Bank Ag has invested 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Raymond James & Associates holds 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 72,204 shares. Jefferies Group also issued estimates for Integra Lifesciences' Q4 2018 earnings at $0.62 EPS, Q3 2019 earnings at $0.66 EPS, FY2019 earnings at $2.64 EPS, FY2020 earnings at $2.98 EPS and FY2021 earnings at $3.41 EPS. Moreover, State Board Of Administration Of Florida Retirement has 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Numeric Investors Lc stated it has 9,300 shares. Magnetar Financial Limited reported 0.01% stake. Sta Wealth Mgmt Lc holds 0.2% or 10,302 shares. Capital Glob Investors has 6.06 million shares. Champlain Inv Limited Liability Company holds 4.54M shares. California Employees Retirement owns 132,002 shares.

In other news, VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences stock in a transaction dated Tuesday, November 14th. Stoneridge Ptnrs Ltd reported 0.09% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). During the same quarter in the prior year, the company posted $0.93 earnings per share. IART's profit will be $43.95M for 20.97 P/E if the $0.56 EPS becomes a reality.

Vertical Research Upgrades Crown (NYSE:CCK) to Buy
The industrial products company reported $1.41 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.41. It dived, as 48 investors sold WAB shares while 133 reduced holdings. 31 funds opened positions while 45 raised stakes.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on February, 22. The company has market cap of $18.68 billion. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue fix and tissue regeneration products, and small bone fixation and joint replacement solutions. It has a 76.87 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural fix products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

ViewRay, Inc., through its subsidiary, ViewRay Technologies, Inc., designs, makes, and markets radiation therapy systems. The Company's products are primarily used in automatic identification, data collection, and personal identification applications.

The stock increased 1.99% or $2.06 during the last trading session, reaching $105.77. About 4.03M shares traded. ViewRay, Inc. (NASDAQ:VRAY) has risen 34.94% since January 5, 2017 and is uptrending. It has outperformed by 19.67% the S&P500.

Like this: